Sign in

    Amir Trabelsi

    Research Analyst at Oppenheimer & Co. Inc.

    Amir Trabelsi is an Equity Analyst at Oppenheimer & Co. Inc., focusing on coverage within the pharmaceuticals and biotechnology sectors. He provides research and recommendations on companies such as 10X Genomics, Bruker, Curio Bioscience, and Vizgen, with investment calls reflected in sector litigation tracking and recent performance studies. Trabelsi began his analyst career after managerial roles in technology firms and entrepreneurial ventures and joined Oppenheimer to further specialize in life sciences equity research. He holds FINRA registration and maintains current securities analyst licenses, with his work recognized for domain expertise and analytical rigor.

    Amir Trabelsi's questions to GLOBUS MEDICAL (GMED) leadership

    Amir Trabelsi's questions to GLOBUS MEDICAL (GMED) leadership • Q4 2024

    Question

    Amir Trabelsi, on for Steve Lichtman at Oppenheimer, asked if there were any changes in the capital purchasing appetite of customers, such as a shift to rentals, and requested a breakdown of the 2025 sales guidance by segment.

    Answer

    CFO Keith Pfeil responded that the capital market remains strong with a cyclical nature, and while Globus offers flexible options like rentals and leases, the vast majority of sales continue to be outright purchases. He declined to provide a sales guidance breakdown by segment, stating the company looks at the business in aggregate and is comfortable with its overarching guidance.

    Ask Fintool Equity Research AI